

- **Name:** Seock-Ah Im
- **Current Position & Affiliation:** Professor
Seoul National University Hospital
Seoul National University College of Medicine
Cancer Research Institute, Seoul National University
- **Country:** Korea

• **Educational Background:**

1991 : M.D. Ewha Womans University, College of Medicine, Seoul, Korea

1995 : M.S. Ewha Womans University, College of Medicine, Seoul, Korea

1999 : Ph.D. Ewha Womans University, College of Medicine, Seoul, Korea

• **Professional Experience:**

1996–1997: Clinical Fellowship, Division of Hematology-Medical Oncology,
Dept. of Internal Medicine, Seoul National University Hospital.

1997–1998: Research Fellow at Division of Internal Medicine, Department of
Neuro-Oncology, M.D. Anderson Cancer Center, Houston, Texas, USA

2000 –2003: Instructor, Assistant Professor, Department of Internal Medicine,
Ewha Womans University, College of Medicine

2008 –2009: Translational Research Scientist, AstraZeneca Oncology R&D center,
Cheshire, UK

2003–Present: Professor, Department of Internal Medicine,
Seoul National University, College of Medicine

• **Professional Organizations:**

2015 –2019: Director of Breast Cancer Committee, Korean Cancer Study Group (KCSG)

2015 –2022: Director of Medical Oncology Center, Seoul National University Cancer Hospital

2018 –2022: Director, Division of Hematology-Medical Oncology,
Department of Internal Medicine, Seoul National University Hospital

2018–2022: Scientific Committee Chair, Korean Society of Medical Oncology(KSMO)

2021–2023: Clinical Practice Guidelines (CPG) Committee Chair,
European Society for Medical Oncology (ESMO)-PAGA

2021–2023: Chairperson of External Cooperation Committee, Korean Cancer Study Group (KCSG)

2020 –2024: International Affairs Committee Chair, Korean Cancer Association (KCA)

2022 –2024: Organizing Committee Chair, Korean Society of Medical Oncology(KSMO)

2019–Present: Director, Cancer Research Institute, Seoul National University

2021– Present: Board of Directors, Translation Research in Oncology (TRIO)

2024–Present: Full Member, Korean Academy of Science and Technology (KAST)

• Main Scientific Publications:

1. Na D, Chae J, Cho SY, Kang W, Lee A, Min S, Kang J, Kim MJ, Choi J, Lee W, Shin D, Min A, Kim YJ, Lee KH, Kim TY, Suh YS, Kong SH, Lee HJ, Kim WH, Park H, **Im SA**, Yang HK, Lee C, Kim JI. Predictive biomarkers for 5-fluorouracil and oxaliplatin-based chemotherapy in gastric cancers via profiling of patient-derived xenografts. *Nat Commun*. 2021 Aug 10;12(1):4840.
2. Kim YJ, **Im SA**, Kim HG, Oh SY, Lee KW, et al., A phase II trial of S-1 and cisplatin in patients with metastatic or relapsed biliary tract cancer. *Ann Oncol*. 2008 Jan;19(1):99-103.
3. Park YH, **Im SA**, Park K, Wen J, Lee KH, et al., Longitudinal multi-omics study of palbociclib resistance in HR-positive/HER2-negative metastatic breast cancer. *Genome Med*. 2023 Jul 20;15(1):55.
4. Hurvitz SA, Hegg R, Chung WP, **Im SA**, Jacot W, Ganju V, Chiu JWY, Xu B, et al., Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial. *Lancet*. 2023 Jan 14;401(10371):105-117.
5. André F, Hee Park Y, Kim SB, Takano T, **Im SA**, Borges G, Lima JP, et al., Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial. *Lancet*. 2023 May 27;401(10390):1773-1785.
6. Schmid P, Cortes J, Dent R, Pusztai L, McArthur H, Kümmel S, Bergh J, Denkert C, Park YH, Hui R, Harbeck N, Takahashi M, Untch M, Fasching PA, Cardoso F, Andersen J, Patt D, Danso M, Ferreira M, Mouret-Reynier MA, **Im SA**, Ahn JH, Gion M, Baron-Hay S, Boileau JF, Ding Y, Tryfonidis K, Aktan G, Karantza V, O'Shaughnessy J; KEYNOTE-522 Investigators. Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer. *N Engl J Med*. 2022 Feb 10;386(6):556-567.
7. Cortés J, Kim SB, Chung WP, **Im SA**, Park YH, Hegg R, Kim MH, et al., Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer. *N Engl J Med*. 2022 Mar 24;386(12):1143-1154.
8. Modi S, Jacot W, Yamashita T, Sohn J, Vidal M, Tokunaga E, Tsurutani J, Ueno NT, Prat A, Chae YS, Lee KS, Niikura N, Park YH, Xu B, Wang X, Gil-Gil M, Li W, Pierga JY, **Im SA**, Moore HCF, Rugo HS, et al., Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer. *N Engl J Med*. 2022 Jul 7;387(1):9-20.
9. Cortes J, Rugo HS, Cescon DW, **Im SA**, Yusof MM, Gallardo C, Lipatov O, et al., Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer. *N Engl J Med*. 2022 Jul 21;387(3):217-226.
10. Slamon D, Lipatov O, Nowecki Z, McAndrew N, Kukiela-Budny B, Stroyakovskiy D, Yardley DA, Huang CS, Fasching PA, Crown J, Bardia A, Chia S, **Im SA**, Ruiz-Borrego M, et al., Ribociclib plus Endocrine Therapy in Early Breast Cancer. *N Engl J Med*. 2024 Mar 21;390(12):1080-1091.
11. Bardia A, Hu X, Dent R, Yonemori K, Barrios CH, O'Shaughnessy JA, Wildiers H, Pierga JY, Zhang Q, Saura C, Biganzoli L, Sohn J, **Im SA**, Lévy C, et al., Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer. *N Engl J Med*. 2024 Dec 5;391(22):2110-2122.